Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent ...
Daily Mail on MSN

Hope for thousands as new drug cuts prostate cancer relapse risk by a third

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

NHS likely to reject ‘holy grail’ cancer test

Blood test that detects four times as many cases as standard screening ‘deemed too ineffective for widespread use’ ...
a-z-animals

House Cats May Help Unlock New Cancer Treatments

Quick Take Cancer in Cats and Humans Studying Cat Cancers How Important Is This for Cancer Researc... A newly discovered genetic link between cat and human cancer may have major implications for the ...